Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer

被引：0
|
作者：
Takahito Masuda
Hiroshi Fujimoto
Ryotaro Teranaka
Masayuki Kuroda
Yasuyuki Aoyagi
Takeshi Nagashima
Takafumi Sangai
Mamoru Takada
Ayako Nakagawa
Yoshitaka Kubota
Koutaro Yokote
Masayuki Ohtsuka
机构：
[1] Chiba University Graduate School of Medicine,Department of General Surgery
[2] Chiba University Hospital,Center for Advanced Medicine
[3] CellGenTech,Department of Plastic, Reconstructive, and Aesthetic Surgery
[4] Inc.,Department of Clinical Cell Biology and Medicine
[5] Chiba University Graduate School of Medicine,undefined
[6] Chiba University Graduate School of Medicine,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 180卷
关键词：
Breast cancer; Adipocytes; Gene therapy; Human epidermal growth factor receptor 2; Monoclonal antibody; Molecular target therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：625 / 634
页数：9
相关论文
共 50 条
  • [1] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
    Masuda, Takahito
    Fujimoto, Hiroshi
    Teranaka, Ryotaro
    Kuroda, Masayuki
    Aoyagi, Yasuyuki
    Nagashima, Takeshi
    Sangai, Takafumi
    Takada, Mamoru
    Nakagawa, Ayako
    Kubota, Yoshitaka
    Yokote, Koutaro
    Ohtsuka, Masayuki
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 625 - 634
  • [2] Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
    Teranaka, Ryotaro
    Fujimoto, Hiroshi
    Masuda, Takahito
    Kuroda, Masayuki
    Aoyagi, Yasuyuki
    Nagashima, Takeshi
    Takada, Mamoru
    Sakakibara, Junta
    Yamada, Hideyuki
    Yamamoto, Hiroto
    Kubota, Yoshitaka
    Ohtsuka, Masayuki
    [J]. BREAST CANCER, 2023, 30 (06) : 1018 - 1027
  • [3] Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
    Ryotaro Teranaka
    Hiroshi Fujimoto
    Takahito Masuda
    Masayuki Kuroda
    Yasuyuki Aoyagi
    Takeshi Nagashima
    Mamoru Takada
    Junta Sakakibara
    Hideyuki Yamada
    Hiroto Yamamoto
    Yoshitaka Kubota
    Masayuki Ohtsuka
    [J]. Breast Cancer, 2023, 30 : 1018 - 1027
  • [4] Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes
    Watanabe, Kenichi
    Hagio, Kanako
    Baba, Motoi
    Ikarashi, Mayuko
    Sato, Masako
    Tomioka, Nobumoto
    Takahashi, Masato
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [5] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    [J]. CANCER CONTROL, 2023, 30
  • [6] Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy
    Sethunath, Vidyalakshmi
    Hu, Huizhong
    De Angelis, Carmine
    Veeraraghavan, Jamunarani
    Qin, Lanfang
    Rimawi, Motthaffar F.
    Osborne, Kent C.
    Schiff, Rachel
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [7] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    [J]. CANCER CONTROL, 2022, 29
  • [8] HER2-positive breast cancer: From trastuzumab to innovatory anti-HER2 strategies
    Whenham, Nicolas
    D'Hondt, Veronique
    Piccart, Martine J.
    [J]. CLINICAL BREAST CANCER, 2008, 8 (01) : 38 - 49
  • [9] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [10] Margetuximab Anti-HER2 monoclonal antibody Treatment of metastatic HER2-positive breast cancer Treatment of HER2-positive gastric or gastroeso-phageal junction cancer
    Hanna, K. S.
    [J]. DRUGS OF THE FUTURE, 2021, 46 (03) : 191 - 195
12345